Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background-Reference-Cited by-同舟云学术

Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Published:2012-01-31 Issue:4 Volume:11 Page:873-887
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Davies Barry R.,Greenwood Hannah,Dudley Phillippa,Crafter Claire,Yu De-Hua,Zhang Jingchuan,Li Jing,Gao Beirong,Ji Qunsheng,Maynard Juliana,Ricketts Sally-Ann,Cross Darren,Cosulich Sabina,Chresta Christine C.,Page Ken,Yates James,Lane Clare,Watson Rebecca,Luke Richard,Ogilvie Donald,Pass Martin

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 366 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications;Seminars in Cancer Biology;2024-11

2. Autophagy modulation in cancer therapy: Challenges coexist with opportunities;European Journal of Medicinal Chemistry;2024-10

3. CRLF1 bridges AKT and mTORC2 through SIN1 to inhibit pyroptosis and enhance chemo-resistance in ovarian cancer;Cell Death & Disease;2024-09-10

4. HN1-mediated activation of lipogenesis through Akt-SREBP signaling promotes hepatocellular carcinoma cell proliferation and metastasis;Cancer Gene Therapy;2024-09-09

5. Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial;The Lancet Oncology;2024-09